VRTX126 / Vrise Therap - LARVOL DELTA

KRASG12C Inhibitor, VRTX126 in combination with Tyrosine Kinase Inhibitor, leads to pronounced and effective response in G12C-mutated cancers. (AACR-NCI-EORTC 2022) - "In vitro study using a combination matrix of VRTX126 and Afatinib indicated synergistic effect leading to a significant dose reduction of TKI which was further confirmed in in-vivo settings. This paves way for safely combining VRTX126 with multiple precision medicines, including TKIs at significantly lower doses. No"

Combination therapy • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • DUSP6 • KRAS